In TX-28, there are **73,519 people enrolled in a Medicare Part D plan** and **361,305 people enrolled in private health insurance** – all of whom stand to benefit from the passage of *H.R. 3 The Lower Drug Costs Now Act.*

### Source of Prescription Drug Coverage

<table>
<thead>
<tr>
<th>Source of Prescription Drug Coverage</th>
<th>TX-28 Residents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicare Prescription Drug Plan (PDP)</td>
<td>5.3% (39,772 People)</td>
</tr>
<tr>
<td>Medicare Advantage Prescription Drug (MA-PD)</td>
<td>4.3% (32,025 People)</td>
</tr>
<tr>
<td>Medicare Part D (Any Plan)</td>
<td>9.8% (73,519 People)</td>
</tr>
<tr>
<td>Private Health Insurance</td>
<td>48% (361,305 People)</td>
</tr>
</tbody>
</table>

Source: Committee tabulations of U.S. Census Bureau, 2017 American Community Survey 1-year estimates

Note: Some insurance categories include people who have multiple sources of coverage. Some insurance categories are not included. Therefore, totals will not sum up to 100%.

### Cancer Medications

There are an estimated **15 million Americans living with cancer**, including **124,890 annual cancer diagnoses in Texas.** In 2019, an estimated **41,300 Texas residents will die of cancer.** Most cancer medications cost patients **over $100,000 annually** in the U.S., which is why 90 percent of Americans say cancer drugs are too expensive.

#### BREAST CANCER

In 2019, an estimated **18,750 women in Texas will be diagnosed with breast cancer.**

H.R. 3 can lower the average total cost of the breast cancer medication Ibrance by 65% from **$69,000 to $23,900 per year.**

Source: Committee tabulations of American Cancer Society, 2019 Cancer Statistics Center, and 2018 pharmaceutical price data from recognized price sources.

#### LEUKEMIA

In 2019, an estimated **4,820 people in Texas will be diagnosed with leukemia.**

H.R. 3 can lower the average total cost of the leukemia medication Tasigna by 71% from **$93,700 to $27,400 per year.**

Source: Committee tabulations of American Cancer Society, 2019 Cancer Statistics Center, and 2018 pharmaceutical price data from recognized price sources.

#### PROSTATE CANCER

In 2019, an estimated **10,660 people in Texas will be diagnosed with prostate cancer.**

H.R. 3 can lower the average total cost of the prostate cancer medication Zytiga by 66% from **$109,500 to $37,400 per year.**

Source: Committee tabulations of American Cancer Society, 2019 Cancer Statistics Center, and 2018 pharmaceutical price data from recognized price sources.
**H.R. 3 will Reduce Drug Costs for Millions of Americans**

<table>
<thead>
<tr>
<th>ARTHRITIS</th>
<th>ASTHMA</th>
</tr>
</thead>
<tbody>
<tr>
<td>19.8% of Texas residents have arthritis, 32% of whom experience severe joint pain because of it. H.R. 3 can lower their total costs on most arthritis drugs from about $40,000 to $10,000 per year.</td>
<td>About 7.3% or 1,543,064 Texas residents live with asthma. H.R. 3 can lower their total costs on most asthma drugs from about $1,400 to $270 per year.</td>
</tr>
</tbody>
</table>

Source: Arthritis Foundation, Committee tabulations of 2018 pharmaceutical price data from recognized price sources.

<table>
<thead>
<tr>
<th>HIV/AIDS</th>
<th>MULTIPLE SCLEROSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>In 2015, 4,358 Texas residents were diagnosed with HIV. H.R. 3 can lower their total costs on most HIV drugs from about $15,000 to $6,000 per year.</td>
<td>One million people are living with Multiple Sclerosis (MS) in the United States. H.R. 3 can lower their total costs on most MS drugs from about $40,000 to $13,000 per year.</td>
</tr>
</tbody>
</table>

Source: Centers for Disease Control and Prevention, Committee tabulations of 2018 pharmaceutical price data from recognized price sources.

---

**Insulin**

**30.3 million Americans** live with diabetes, including **2,333,065 people in Texas**. Over the past decade, the price of insulin has **increased 197 percent**, and Medicare Part D spending on insulin has **increased 840 percent**.

**DIABETES**

In Texas, there are an estimated **2,333,065 people living with diabetes**.

Source: Committee tabulations of Center for Disease Control and Prevention, 2017 Diagnosed Diabetes Statistics, and 2018 pharmaceutical price data from recognized price sources.

**INSULIN COSTS**

For the most commonly used insulin medications, Texas residents spend anywhere from $1,200 to $20,000 annually.

H.R. 3 can lower the average total cost of the insulin NovoLOG Flexpen by 76% from about **$19,800 to $4,800 per year**.

Under H.R. 3, Texas residents could spend **3.5 times less on insulin**.

Under H.R. 3, some commonly used insulins can cost as little as **$400 per year**.

Source: Committee tabulations of 2018 pharmaceutical price data from recognized price sources.